DE69132045D1 - Monoklonale Antikörper gegen menschlichen Tumornekrosefaktor alpha - Google Patents

Monoklonale Antikörper gegen menschlichen Tumornekrosefaktor alpha

Info

Publication number
DE69132045D1
DE69132045D1 DE69132045T DE69132045T DE69132045D1 DE 69132045 D1 DE69132045 D1 DE 69132045D1 DE 69132045 T DE69132045 T DE 69132045T DE 69132045 T DE69132045 T DE 69132045T DE 69132045 D1 DE69132045 D1 DE 69132045D1
Authority
DE
Germany
Prior art keywords
monoclonal antibodies
antibodies against
necrosis factor
tumor necrosis
human tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69132045T
Other languages
English (en)
Other versions
DE69132045T2 (de
Inventor
Elena Barbanti
Marta Ghislierie
Fabrizio Marcucci
Domenico Trizio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10687639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69132045(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Publication of DE69132045D1 publication Critical patent/DE69132045D1/de
Application granted granted Critical
Publication of DE69132045T2 publication Critical patent/DE69132045T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69132045T 1990-12-28 1991-12-19 Monoklonale Antikörper gegen menschlichen Tumornekrosefaktor alpha Revoked DE69132045T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909028123A GB9028123D0 (en) 1990-12-28 1990-12-28 Monoclonal antibodies against human tumor necrosis factor alpha

Publications (2)

Publication Number Publication Date
DE69132045D1 true DE69132045D1 (de) 2000-04-20
DE69132045T2 DE69132045T2 (de) 2000-09-14

Family

ID=10687639

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69132045T Revoked DE69132045T2 (de) 1990-12-28 1991-12-19 Monoklonale Antikörper gegen menschlichen Tumornekrosefaktor alpha

Country Status (22)

Country Link
US (1) US5436154A (de)
EP (1) EP0492448B1 (de)
JP (1) JPH0596A (de)
KR (1) KR920011519A (de)
AT (1) ATE190667T1 (de)
AU (1) AU648617B2 (de)
CA (1) CA2058370C (de)
CZ (1) CZ385791A3 (de)
DE (1) DE69132045T2 (de)
DK (1) DK0492448T3 (de)
ES (1) ES2145735T3 (de)
FI (1) FI916059A (de)
GB (1) GB9028123D0 (de)
GR (1) GR3033374T3 (de)
HU (1) HUT63204A (de)
IE (1) IE914538A1 (de)
IL (1) IL100365A (de)
MX (1) MX9102769A (de)
NZ (1) NZ241048A (de)
PT (1) PT99887A (de)
RU (1) RU2073722C1 (de)
ZA (1) ZA9110127B (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69027121T3 (de) * 1989-08-07 2001-08-30 Peptech Ltd., Dee Why Bindeligande für tumornekrosisfaktor
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
GB9000644D0 (en) * 1990-01-11 1990-03-14 Erba Carlo Spa New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
WO1993001211A1 (en) * 1991-07-05 1993-01-21 Peptide Technology Limited Peptide which abrogates tnf and/or lps toxicity
EP0525570A3 (en) * 1991-07-31 1993-10-06 Miles Inc. Anti-idiotypic antibodies that mimic tnf
IT1254315B (it) * 1992-03-27 1995-09-14 Mini Ricerca Scient Tecnolog Anticorpi monoclonali anti-idiotipici diretti contro anticorpi anti-tnf.
DE69321909T2 (de) * 1992-08-28 1999-04-01 Bayer Corp., Pittsburgh, Pa. Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
US20050260201A1 (en) * 1993-01-29 2005-11-24 Centocor, Inc. Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins
US5457129A (en) * 1993-05-17 1995-10-10 Research Development Foundation Inhibition of nitric oxide production by retinoic acid
US6193969B1 (en) * 1993-06-03 2001-02-27 Protherics Inc. Antibody fragments in therapy
US6897295B1 (en) * 1993-11-10 2005-05-24 Mochida Pharmaceutical Co., Ltd. Antibodies and fragments thereof to Fas ligand and Fas ligand derived polypeptides
FR2729651A1 (fr) * 1995-01-24 1996-07-26 Rhone Poulenc Chimie Catalyseurs d'ammoxydation et leur procede de preparation
US6096312A (en) * 1995-06-30 2000-08-01 Mochida Pharmaceutical Co., Ltd. Agent for suppressing a reduction of CD4+ lymphocytes
EP0846169B1 (de) * 1995-08-04 2003-03-19 Lek, Tovarna Farmacevtskih in Kemicnih Izdelkov, D.D. Monoklonale antikörper gegen lösliche tnf-alpha rezeptoren p55 und p75 als auch gegen tnf-alpha und dessen analogen
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
NZ512006A (en) 1996-02-09 2005-05-27 Abbott Biotech Ltd Medical treatment with human TNF-alpha antibodies
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
US20030228310A1 (en) * 1996-12-23 2003-12-11 Advanced Biotherapy, Inc. Treatment of skin diseases
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US7494652B1 (en) 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US20030009013A1 (en) * 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE60045240D1 (de) * 1999-03-02 2010-12-30 Centocor Inc Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma
DE60023123T2 (de) * 1999-03-18 2006-06-22 Celgene Corp. Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine
US20060018907A1 (en) * 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
US20050249735A1 (en) * 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US20110195063A1 (en) * 2000-08-07 2011-08-11 Centocor, Inc. Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
US6709655B2 (en) 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
CA2439852A1 (en) * 2001-03-02 2002-09-12 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI327597B (en) * 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
AU2003226065B2 (en) * 2002-04-12 2009-02-26 Ludwig Institute For Cancer Research, Ltd Recombinant anti-interleukin-9 antibodies
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
ES2347239T3 (es) 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
WO2005067477A2 (en) * 2003-12-08 2005-07-28 Centocor, Inc. Anti-human lymphotoxin alpha antibodies, compositions, methods and uses
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
EP2422811A2 (de) 2004-10-27 2012-02-29 MedImmune, LLC Modulation von Antikörperspezifität mittels Anpassung der Affinität zu verwandten Antigenen
AU2006246721B2 (en) 2005-05-16 2012-12-13 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
KR20150006085A (ko) 2006-04-05 2015-01-15 애브비 바이오테크놀로지 리미티드 항체 정제
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2043603A4 (de) 2006-07-11 2010-10-27 Arubor Corp Prävention und therapie von rhinosinusitis mit proinflammatorischen zytokinhemmern
AU2007284690A1 (en) 2006-08-10 2008-02-21 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
US20080279851A1 (en) 2007-05-07 2008-11-13 Medlmmune, Llc Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
MX2010001319A (es) * 2007-08-07 2010-06-01 Chugai Pharmaceutical Co Ltd Metodo para producir proteinas heterogeneas.
US20090038182A1 (en) * 2007-08-09 2009-02-12 Lans Maris J Footwear with built-in scale
WO2009030285A1 (en) * 2007-09-07 2009-03-12 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
NZ601913A (en) 2008-01-15 2014-02-28 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
BRPI0921845A2 (pt) 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
RU2571489C2 (ru) * 2009-10-26 2015-12-20 Нестек С.А. Способы выявления препаратов и аутоантител против tnf
EP2630495B1 (de) 2010-10-18 2017-02-08 Nestec S.A. Verfahren zur bestimmung von gegen medikamente gerichtete antikörperisotypen
CN103502815B (zh) * 2011-02-17 2015-09-23 雀巢产品技术援助有限公司 检测针对抗-TNFα药物的自身抗体的测定法
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2015067913A1 (en) 2013-11-07 2015-05-14 Diagnodus Limited Biomarkers
RU2013158256A (ru) 2011-07-06 2015-07-10 Нестек С.А. АНАЛИЗЫ ДЛЯ ОБНАРУЖЕНИЯ НЕЙТРАЛИЗУЮЩИХ АУТОАНТИТЕЛ ДЛЯ БИОЛОГИЧЕСКОЙ ТЕРАПИИ TNFα
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
RU2525663C1 (ru) * 2013-03-04 2014-08-20 Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) ШТАММ ГИБРИДНЫХ КУЛЬТИВИРУЕМЫХ КЛЕТОК ЖИВОТНЫХ Mus musculus 2F9-ПРОДУЦЕНТ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ, СПЕЦИФИЧНЫХ К ЛИЗОСТАФИНУ И ИНГИБИРУЮЩИХ ЕГО ЛИТИЧЕСКУЮ АКТИВНОСТЬ
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016088104A2 (en) 2014-12-05 2016-06-09 Nestec S.A. Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
KR102562006B1 (ko) * 2020-11-09 2023-08-02 바디텍메드(주) 항tnf-알파 약물 모니터링을 위한 신속 검출 키트

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US5075236A (en) * 1987-04-24 1991-12-24 Teijin Limited Method of detecting kawasaki disease using anti-tumor necrosis antibody
GB8805792D0 (en) * 1988-03-11 1988-04-13 Celltech Ltd Medicaments
DE3823804A1 (de) * 1988-07-14 1990-01-18 Basf Ag Neutralisation der in vitro und in vivo toxischen eigenschaften von tnf-(alpha) durch monoklonale antikoerper und den davon abgeleiteten fragmenten
WO1990000902A1 (en) * 1988-07-18 1990-02-08 Chiron Corporation Monoclonal antibodies reactive with cachectin
WO1990001950A1 (en) * 1988-08-19 1990-03-08 Celltech Limited Pharmaceutical products for anti-neoplastic therapy
DE4037604A1 (de) * 1990-04-25 1991-10-31 Bayer Ag Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen

Also Published As

Publication number Publication date
ATE190667T1 (de) 2000-04-15
EP0492448B1 (de) 2000-03-15
KR920011519A (ko) 1992-07-24
FI916059A0 (fi) 1991-12-20
MX9102769A (es) 1992-06-01
IL100365A (en) 1996-01-31
ES2145735T3 (es) 2000-07-16
GB9028123D0 (en) 1991-02-13
DE69132045T2 (de) 2000-09-14
EP0492448A1 (de) 1992-07-01
PT99887A (pt) 1992-12-31
CA2058370C (en) 2004-04-27
HU914127D0 (en) 1992-03-30
DK0492448T3 (da) 2000-07-10
IE914538A1 (en) 1992-07-01
AU648617B2 (en) 1994-04-28
ZA9110127B (en) 1992-09-30
FI916059A (fi) 1992-06-29
US5436154A (en) 1995-07-25
JPH0596A (ja) 1993-01-08
CA2058370A1 (en) 1992-06-29
NZ241048A (en) 1993-07-27
CZ385791A3 (en) 1993-05-12
GR3033374T3 (en) 2000-09-29
IL100365A0 (en) 1992-09-06
RU2073722C1 (ru) 1997-02-20
AU8970391A (en) 1992-07-02
HUT63204A (en) 1993-07-28

Similar Documents

Publication Publication Date Title
ATE190667T1 (de) Monoklonale antikörper gegen menschlichen tumornekrosefaktor alpha
ATE114724T1 (de) Antikörper gegen tnf-bindungsprotein i und deren f(ab)-fragmente.
EA200200427A1 (ru) Рецептор april (bcma) и его применения
ZA876807B (en) Monoclonal antibodies against human tumor necrosis factor(tnf),and use thereof
CA2128511A1 (en) Monomeric and dimeric antibody-fragment fusion proteins
DE69230545D1 (de) Antikörperderivate
DE69504959D1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE397659T1 (de) Polyklonale antikörper gegen den menschlichen alpha-pdgf-rezeptor und dessen verwendung
DE3684264D1 (de) Hybridomazellen und deren monoklonale antikoerper gegen den humanen pluropotenten granulozyten-kolonie stimulierenden faktor.
AU584690B2 (en) E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
DE3687044D1 (de) Hybridomen-tumor-zellinien und deren monoklonale antikoerper gegen thaumatin.
AU1974592A (en) Monoclonal antibodies against human tnf-binding protein i (tnf-bp i)
FI86255B (fi) Monoklonal antiurokinase-antikropp, den innehaollande matris och biokemiska testpackningar, i vilka den anvaendes.
ATE93895T1 (de) Monoklonale antikoerper gegen humanen tumonekrosefaktor (tnf) und deren verwendung.
SE9601231D0 (sv) Monoclonal antibody
ES1027113U (es) Tubo para recogida de orina.
ITMI910467U1 (it) Rivestimento di gallerie mediante l'impiego di lastre in policarbonato e mezzi adatti allo scopo.
NO914119D0 (no) Monoklonalt antistoff for differensiering av platecellekarsinom-antigener og fremgangsmaate for dets anvendelse
DK41890A (da) Immunosorbent og dets anvendelse

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation